On May 11th 2017, Cardior Pharmaceuticals announced the completion of a €15 million Series A financing round led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Meyers-Squibb (BMS), BioMedPartners and High-Tech Gründerfonds (HTGF). Cardior is pioneering its proprietary RNA technology to revolutionise predicting and treating heart failure. The molecular targets are non-coding RNAs linked to heart failure development that simultaneously control cardiac growth and calcium handling/contractility of cardiomyocytes. The targeting of certain specific non-coding RNAs reverses maladaptive cardiac remodelling and restores normal cardiac function.
Gill Jennings and Every LLP advised the investor Syndicate led by LSP on the IP-related aspects of the transaction, including due diligence and freedom to operate analysis. The GJE team was led by partner John Jappy, assisted by Alice Baker.